Teva Pharmaceutical

TEVA-N

NYSE:TEVA

11.50
0.07 (0.61%)
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company headquartered in Petah Tikva, Israel.
More at Wikipedia

Analysis and Opinions about TEVA-N

Signal
Opinion
Expert
BUY
BUY
February 27, 2020
It's time to get back in. They all went crazy and then slid on sympathy when valiant went bust. There is tremendous value here. His model price is $21.26 or 63% upside. They presented earnings and the balance sheet looks great.
Show full opinionHide full opinion
It's time to get back in. They all went crazy and then slid on sympathy when valiant went bust. There is tremendous value here. His model price is $21.26 or 63% upside. They presented earnings and the balance sheet looks great.
HOLD
HOLD
November 28, 2019
Generic brand companies like Teva have struggled in the last 5 years has they competed with each others. Pfizer is in the process of buying one of their competitors and the Pfizer stock dropped 5$ on the announcement. Doesn't own Teva, purchased United Heatlth recently. You can hold but it's not a name he would hold due to the risk and they have no value added.
Show full opinionHide full opinion
Generic brand companies like Teva have struggled in the last 5 years has they competed with each others. Pfizer is in the process of buying one of their competitors and the Pfizer stock dropped 5$ on the announcement. Doesn't own Teva, purchased United Heatlth recently. You can hold but it's not a name he would hold due to the risk and they have no value added.
DON'T BUY
DON'T BUY
August 15, 2019
They went from an in incredibly well managed drug company and then management decided to develop their own drugs and make mistakes. It is difficult to unwind these problems. Turning around a company like this will be difficult because of the debt. This is a highly speculative stock.
Show full opinionHide full opinion
They went from an in incredibly well managed drug company and then management decided to develop their own drugs and make mistakes. It is difficult to unwind these problems. Turning around a company like this will be difficult because of the debt. This is a highly speculative stock.
DON'T BUY
DON'T BUY
July 17, 2019
He sold it at a 50% loss due to price declines in generic drugs. That deflation has decreased lately, which is sort of good news. One of their big drugs came off patent, too.
Show full opinionHide full opinion
He sold it at a 50% loss due to price declines in generic drugs. That deflation has decreased lately, which is sort of good news. One of their big drugs came off patent, too.
DON'T BUY
DON'T BUY
July 3, 2019
A generic drug company that has had troubled times as pricing is becoming very competitive. Buyers are consolidating and squeezing margins. They have a MS drug that was a market leader, but now there are others competing. He would rather own brand name drug companies that can become leaders in their field.
Show full opinionHide full opinion
A generic drug company that has had troubled times as pricing is becoming very competitive. Buyers are consolidating and squeezing margins. They have a MS drug that was a market leader, but now there are others competing. He would rather own brand name drug companies that can become leaders in their field.
DON'T BUY
DON'T BUY
July 2, 2019
It has done very well. But they made a huge acquisitions three years ago, taking on a lot of debt. They went through several CEOs. The generic drug space is tough and competitive. Generic drug pricing is limited as we head towards a U.S. election; generics are a target of politicians. Also, there are many lawsuits in the generic drug industry. Generics should do better after the election.
Show full opinionHide full opinion
It has done very well. But they made a huge acquisitions three years ago, taking on a lot of debt. They went through several CEOs. The generic drug space is tough and competitive. Generic drug pricing is limited as we head towards a U.S. election; generics are a target of politicians. Also, there are many lawsuits in the generic drug industry. Generics should do better after the election.
DON'T BUY
DON'T BUY
May 22, 2019
He is more content owning the major pharma versus generic producers. The competition in the space too intense. They have been involved in the manufacturing of opiod based drugs, which could come under regulatory pressure.
Show full opinionHide full opinion
He is more content owning the major pharma versus generic producers. The competition in the space too intense. They have been involved in the manufacturing of opiod based drugs, which could come under regulatory pressure.
COMMENT
COMMENT
May 3, 2019
There is hope for it. Good news is the generic price declines have subsided, but "less declines" is not where he wants to be right now. Challenged in the next 12-18 months. Could go to low 20s, but structural headwinds for the business.
Show full opinionHide full opinion
There is hope for it. Good news is the generic price declines have subsided, but "less declines" is not where he wants to be right now. Challenged in the next 12-18 months. Could go to low 20s, but structural headwinds for the business.
BUY
BUY
March 11, 2019
He'd buy it here. It won't go much lower than current levels based on the chart.
Show full opinionHide full opinion
He'd buy it here. It won't go much lower than current levels based on the chart.
DON'T BUY
DON'T BUY
February 13, 2019
They do generic drugs, the largest player in the world. They're smart and great at what they do. But they made a big acqusition that pressured their margins and hurt the company. But management has since changed and the company is recovering. They're still reducing their debt. TEVA should continue to grow. But this turnaround will take time.
Show full opinionHide full opinion
They do generic drugs, the largest player in the world. They're smart and great at what they do. But they made a big acqusition that pressured their margins and hurt the company. But management has since changed and the company is recovering. They're still reducing their debt. TEVA should continue to grow. But this turnaround will take time.
BUY
BUY
December 7, 2018
TEVA vs. GSK Teva is in turnaround with a lot of debt to pay off. They need a boast from their future products moving forward. GSK is higher quality with higher credit rating, and lack Teva's debt woes. GSK is the better bet.
Show full opinionHide full opinion
TEVA vs. GSK Teva is in turnaround with a lot of debt to pay off. They need a boast from their future products moving forward. GSK is higher quality with higher credit rating, and lack Teva's debt woes. GSK is the better bet.
SELL
SELL
December 6, 2018
A great company. Generics are fantastic. There are internal issues. A lot of people are getting lured here by single digit earnings growth. The fundamental picture is not strong here. He would take the loss. He would look at an ETF if you want to stay invested in Pharma. (Analysts’ price target is $23.00)
Show full opinionHide full opinion
A great company. Generics are fantastic. There are internal issues. A lot of people are getting lured here by single digit earnings growth. The fundamental picture is not strong here. He would take the loss. He would look at an ETF if you want to stay invested in Pharma. (Analysts’ price target is $23.00)
DON'T BUY
DON'T BUY
November 12, 2018
It is a big generics play. It has been run fairly well over the years. They are reducing debt. It is okay. There is going to be a lot of selling pressure at the $30 level. Quarterly numbers are okay but there is so much out there that is better. He would use a health device and equipment ETF (IHI-N).
Show full opinionHide full opinion
It is a big generics play. It has been run fairly well over the years. They are reducing debt. It is okay. There is going to be a lot of selling pressure at the $30 level. Quarterly numbers are okay but there is so much out there that is better. He would use a health device and equipment ETF (IHI-N).
COMMENT
COMMENT
October 1, 2018

Generic drugs. Teva will benefit from an aging population and a growing push by governments to make drugs cheaper. However, Teva has been facing competition from other generic makers. In the long term, though, this will be a winner in this space.

Show full opinionHide full opinion

Generic drugs. Teva will benefit from an aging population and a growing push by governments to make drugs cheaper. However, Teva has been facing competition from other generic makers. In the long term, though, this will be a winner in this space.

WATCH
WATCH
September 5, 2018

A leader in generic pharmaceuticals. It's sold off the past few years and he hasn't look at it recently. Hold on. It's bottoming. Look at its fundamentals. This is the right sector, but do your homework on it.

Show full opinionHide full opinion

A leader in generic pharmaceuticals. It's sold off the past few years and he hasn't look at it recently. Hold on. It's bottoming. Look at its fundamentals. This is the right sector, but do your homework on it.

DON'T BUY
DON'T BUY
August 20, 2018

He used to own it in the mid-2000's when they were positioned to benefit from new drugs coming off patent. This ended around 2011. Today, they have a lot of debt, and face declining drug prices.

Show full opinionHide full opinion

He used to own it in the mid-2000's when they were positioned to benefit from new drugs coming off patent. This ended around 2011. Today, they have a lot of debt, and face declining drug prices.

DON'T BUY
DON'T BUY
August 1, 2018

This became the largest generic drug manufacturer in the world who then took on debt to produce their own drugs. This has not worked out well. He would not be a holder of this, due to the competition in the space and the high debt levels. (Analysts’ price target is $21)

Show full opinionHide full opinion

This became the largest generic drug manufacturer in the world who then took on debt to produce their own drugs. This has not worked out well. He would not be a holder of this, due to the competition in the space and the high debt levels. (Analysts’ price target is $21)

DON'T BUY
DON'T BUY
July 31, 2018

This company lost its identity as it evolved. Was it primarily a drug company or a marketer of generics? Its price dropped substantially after its main drug came off patent. Since then, the CEO left and the Board has reorganized. However, Teva still has a lot of debt. The debt load was moderate, but earnings have fallen so much that the debt has become relatively much more important, making this a risky investment. 16. 3M (MMM-N)(Doesn’t own)(Buy on weakness). This company did very well when value stocks were in favor, and has traded down. It is modestly priced compared to its historical levels, not cheap. This would be a good company to buy at a discount and hold for a long time.

Show full opinionHide full opinion

This company lost its identity as it evolved. Was it primarily a drug company or a marketer of generics? Its price dropped substantially after its main drug came off patent. Since then, the CEO left and the Board has reorganized. However, Teva still has a lot of debt. The debt load was moderate, but earnings have fallen so much that the debt has become relatively much more important, making this a risky investment. 16. 3M (MMM-N)(Doesn’t own)(Buy on weakness). This company did very well when value stocks were in favor, and has traded down. It is modestly priced compared to its historical levels, not cheap. This would be a good company to buy at a discount and hold for a long time.

DON'T BUY
DON'T BUY
May 4, 2018

Generic drug manufacturer. Too many operational issues on this company for them to buy it. Probably closer to the bottom but they would like to see more quarters of solid turn-around. They like other companies better in the space. (Analysts’ price target is $18.00)

Show full opinionHide full opinion

Generic drug manufacturer. Too many operational issues on this company for them to buy it. Probably closer to the bottom but they would like to see more quarters of solid turn-around. They like other companies better in the space. (Analysts’ price target is $18.00)

BUY
BUY
April 26, 2018

An Israeli company that trades in the US. The largest generic pharmaceutical company in the world. They went through a difficult management period after its founder passed away. The important part of the generics is not really the molecule part (if you have smart people you can copy the molecules). The important part is the legal aspect. And here this company is very very strong. It is going to take a while to restructure the company, but they have a great franchise. Over a 3 to 5 years’ time horizon it is a great story to buy.

Show full opinionHide full opinion

An Israeli company that trades in the US. The largest generic pharmaceutical company in the world. They went through a difficult management period after its founder passed away. The important part of the generics is not really the molecule part (if you have smart people you can copy the molecules). The important part is the legal aspect. And here this company is very very strong. It is going to take a while to restructure the company, but they have a great franchise. Over a 3 to 5 years’ time horizon it is a great story to buy.

DON'T BUY
DON'T BUY
March 21, 2018

Teva or Pfizer? He sold Teva 18 months ago. Generic drug prices are under pressure though have levelled off. Their migraine drug has struggled. Instead, he prefers Pfizer with 140 drugs generating $100 million in revenues. They make good acquisitions and are enjoying great progress in oncology. They're also repatriating $24.5 billion with $5 million going to buybacks. Just announced they want to sell their consumer products division, so the impact of this is unknown. 12x forward earnings. Fabulously run company. Talk of major acquisitions. Happy to hold this.

Show full opinionHide full opinion

Teva or Pfizer? He sold Teva 18 months ago. Generic drug prices are under pressure though have levelled off. Their migraine drug has struggled. Instead, he prefers Pfizer with 140 drugs generating $100 million in revenues. They make good acquisitions and are enjoying great progress in oncology. They're also repatriating $24.5 billion with $5 million going to buybacks. Just announced they want to sell their consumer products division, so the impact of this is unknown. 12x forward earnings. Fabulously run company. Talk of major acquisitions. Happy to hold this.

BUY
BUY
March 14, 2018

He thinks the generic drug space is the cheapest sector out there. Valeant impacted this space severely. He holds this and so does Warren Buffet. He likes this space, but bought it at a lower price. He sees fair value at $25.11 – a 30% upside potential.

Show full opinionHide full opinion

He thinks the generic drug space is the cheapest sector out there. Valeant impacted this space severely. He holds this and so does Warren Buffet. He likes this space, but bought it at a lower price. He sees fair value at $25.11 – a 30% upside potential.

DON'T BUY
DON'T BUY
February 13, 2018

Telepharmaceuticals is a scandal in Israel where he's just visited. Teva is the leader there. Their problems are deep and broad, from Teva's executive suite on down. Sold off his shares a while ago. Don't go near it. Need to get their ship in order.

Show full opinionHide full opinion

Telepharmaceuticals is a scandal in Israel where he's just visited. Teva is the leader there. Their problems are deep and broad, from Teva's executive suite on down. Sold off his shares a while ago. Don't go near it. Need to get their ship in order.

COMMENT
COMMENT
February 7, 2018

Took on a lot of debt to enter the specialty pharma area and stumbled. Suffered a sell-off. But have recently righted the ship, replaced the CEO and announced major cost-cutting. Enjoyed a big rebound, but says be very cautious.

Show full opinionHide full opinion

Took on a lot of debt to enter the specialty pharma area and stumbled. Suffered a sell-off. But have recently righted the ship, replaced the CEO and announced major cost-cutting. Enjoyed a big rebound, but says be very cautious.

COMMENT
COMMENT
January 11, 2018

They are having competition with their biggest product. Mylan (MYL-Q) has come out with a generic alternative to their Copaxone. Their debt has been heavily laden. Just let 10,000-15,000 Israeli employees go. You have to be in a gambling phase, because this could go to zero with their heavy outstanding debt load. They don't have a lot of new products coming out. Instead of playing the stock, he is looking at their bonds.

Show full opinionHide full opinion

They are having competition with their biggest product. Mylan (MYL-Q) has come out with a generic alternative to their Copaxone. Their debt has been heavily laden. Just let 10,000-15,000 Israeli employees go. You have to be in a gambling phase, because this could go to zero with their heavy outstanding debt load. They don't have a lot of new products coming out. Instead of playing the stock, he is looking at their bonds.

DON'T BUY
DON'T BUY
January 9, 2018

A pharmaceutical that does generics as well as branded drugs. The stock has not done well. Has new management, which are cutting costs. Also cut their dividend. There isn’t a lot of visibility on the pipeline, because one of their key branded drugs is seeing more competition and is going generic soon.

Show full opinionHide full opinion

A pharmaceutical that does generics as well as branded drugs. The stock has not done well. Has new management, which are cutting costs. Also cut their dividend. There isn’t a lot of visibility on the pipeline, because one of their key branded drugs is seeing more competition and is going generic soon.

COMMENT
COMMENT
January 9, 2018

This is one he picked many years ago, and it only had one good year. They bought assets from Allergan, and it just went down the toilet. Although it has recovered significantly, turnarounds are hard. He sold his holdings in early 2017, and is not looking at this until it becomes another force again.

Show full opinionHide full opinion

This is one he picked many years ago, and it only had one good year. They bought assets from Allergan, and it just went down the toilet. Although it has recovered significantly, turnarounds are hard. He sold his holdings in early 2017, and is not looking at this until it becomes another force again.

DON'T BUY
DON'T BUY
December 7, 2017

Don’t go near it. They are looking at mid-20% losses this and next year then flat earnings after that.

Show full opinionHide full opinion

Don’t go near it. They are looking at mid-20% losses this and next year then flat earnings after that.

COMMENT
COMMENT
November 28, 2017

The largest generic drug manufacturer. The FDA and other global drug regulators and governments are so focused on driving down the costs of healthcare, including drugs, there is pressure on the entire generics sector. The company has had many other issues as well.

Show full opinionHide full opinion

The largest generic drug manufacturer. The FDA and other global drug regulators and governments are so focused on driving down the costs of healthcare, including drugs, there is pressure on the entire generics sector. The company has had many other issues as well.

COMMENT
COMMENT
November 24, 2017

This has fallen a long way. What you have to think about is, should you take a tax loss. If you haven’t done it yet, it might be worthwhile. You can also buy it back after 30 days and you will have crystallized your loss.

Show full opinionHide full opinion

This has fallen a long way. What you have to think about is, should you take a tax loss. If you haven’t done it yet, it might be worthwhile. You can also buy it back after 30 days and you will have crystallized your loss.

Showing 1 to 30 of 265 entries

Teva Pharmaceutical(TEVA-N) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 1

Neutral - Hold Signals / Votes : 1

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 3

Stockchase rating for Teva Pharmaceutical is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Teva Pharmaceutical(TEVA-N) Frequently Asked Questions

What is Teva Pharmaceutical stock symbol?

Teva Pharmaceutical is a American stock, trading under the symbol TEVA-N on the New York Stock Exchange (TEVA). It is usually referred to as NYSE:TEVA or TEVA-N

Is Teva Pharmaceutical a buy or a sell?

In the last year, 3 stock analysts published opinions about TEVA-N. 1 analyst recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is BUY. Read the latest stock experts' ratings for Teva Pharmaceutical.

Is Teva Pharmaceutical a good investment or a top pick?

Teva Pharmaceutical was recommended as a Top Pick by Brian Acker, CA on 2020-02-27. Read the latest stock experts ratings for Teva Pharmaceutical.

Why is Teva Pharmaceutical stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Teva Pharmaceutical worth watching?

3 stock analysts on Stockchase covered Teva Pharmaceutical In the last year. It is a trending stock that is worth watching.

What is Teva Pharmaceutical stock price?

On 2020-08-14, Teva Pharmaceutical (TEVA-N) stock closed at a price of $11.5.